<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39316666</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-0020</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Blood</Title><ISOAbbreviation>Blood</ISOAbbreviation></Journal><ArticleTitle>Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">blood.2024024667</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1182/blood.2024024667</ELocationID><Abstract><AbstractText>ALPINE (NCT03734016) established the superiority of zanubrutinib over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL); here we present data from the final comparative analysis with extended follow-up. Overall, 652 patients received zanubrutinib (n=327) or ibrutinib (n=325). At an overall median follow-up of 42.5 months, progression-free survival benefit with zanubrutinib vs ibrutinib was sustained (HR: 0.68 [95% CI, 0.54-0.84]), including in patients with del(17p)/TP53 mutation (HR: 0.51 [95% CI, 0.33-0.78]) and across multiple sensitivity analyses. Overall response rate remained higher with zanubrutinib compared with ibrutinib (85.6% vs 75.4%); responses deepened over time with complete response/complete response with incomplete bone marrow recovery rates of 11.6% (zanubrutinib) and 7.7% (ibrutinib). While median overall survival has not been reached in either treatment group, fewer zanubrutinib patients have died than ibrutinib patients (HR: 0.77 [95% CI, 0.55-1.06]). With median exposure time of 41.2 and 37.8 months in zanubrutinib and ibrutinib arms, respectively, the most common non-hematologic adverse events included COVID-19-related infection (46.0% vs 33.3%), diarrhea (18.8% vs 25.6%), upper respiratory tract infection (29.3% vs 19.8%), and hypertension (27.2% vs 25.3%). Cardiac events were lower with zanubrutinib (25.9% vs 35.5%) despite similar rates of hypertension. Incidence of atrial fibrillation/flutter was lower with zanubrutinib vs ibrutinib (7.1% vs 17.0%); no cardiac deaths were reported with zanubrutinib vs six cardiac deaths with ibrutinib. This analysis, at 42.5 months median follow-up, demonstrates that zanubrutinib remains more efficacious than ibrutinib with an improved overall safety/tolerability profile.</AbstractText><CopyrightInformation>Copyright © 2024 American Society of Hematology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Jennifer R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0003-2040-4961</Identifier><AffiliationInfo><Affiliation>Dana-Farber Cancer Institute, Boston, Massachusetts, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eichhorst</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamanna</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Columbia University Medical Center, New York, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><Suffix>M.D</Suffix><AffiliationInfo><Affiliation>Chao Family Comprehensive Cancer Center at UC Irvine Medical Center, Orange, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tam</LastName><ForeName>Constantine S</ForeName><Initials>CS</Initials><Identifier Source="ORCID">0000-0002-9759-5017</Identifier><AffiliationInfo><Affiliation>Alfred Health and Monash University, East Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Lugui</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7438-8277</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jurczak</LastName><ForeName>Wojciech</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-1879-8084</Identifier><AffiliationInfo><Affiliation>Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Keshu</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5467-1377</Identifier><AffiliationInfo><Affiliation>Henan Cancer Hospital, Zhengzhou, China, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Šimkovič</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0331-5334</Identifier><AffiliationInfo><Affiliation>4th Department of Internal Medicine - Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Kralove, Czech Republic, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Jiří</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University Hospital Brno.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillespie-Twardy</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Blue Ridge Cancer Care, Roanoke, Virginia, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrajoli</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>the University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganly</LastName><ForeName>Peter Stephen</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Christchurch Hospital, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinkove</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3645-7988</Identifier><AffiliationInfo><Affiliation>Te Whatu Ora Health New Zealand Capital Coast &amp; Hutt Valley, Wellington, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grosicki</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Silesian Medical University in Katowice, Chorzow, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mital</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical University of Gdańsk, Gdansk, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robak</LastName><ForeName>Tadeusz</ForeName><Initials>T</Initials><Suffix>Prof</Suffix><Identifier Source="ORCID">0000-0002-3411-6357</Identifier><AffiliationInfo><Affiliation>Medical University of Lodz, Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osterborg</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yimer</LastName><ForeName>Habte A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Texas Oncology, Tyler, Texas, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Megan Der Yu</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>BeiGene USA, Inc., San Mateo, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salmi</LastName><ForeName>Tommi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>BeiGene International GmbH, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Liping</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>BeiGene (Beijing) Co., Ltd., China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Beigene, San Mateo,, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>BeiGene USA, Inc., San Mateo, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Aileen Cleary</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>BeiGene, San mateo, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shadman</LastName><ForeName>Mazyar</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3365-6562</Identifier><AffiliationInfo><Affiliation>Fred Hutchinson Cancer Research Center, Seattle, Washington, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood</MedlineTA><NlmUniqueID>7603509</NlmUniqueID><ISSNLinking>0006-4971</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39316666</ArticleId><ArticleId IdType="doi">10.1182/blood.2024024667</ArticleId><ArticleId IdType="pii">517956</ArticleId></ArticleIdList></PubmedData></PubmedArticle>